MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.01972 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von John Mascarenhas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Primary Myelofibrosis. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, NCI NIH HHS, Cancer Research UK.
Abstract (Originalsprache)
PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need. Pelabresib (CPI-0610) is an investigational, selective oral bromodomain and extraterminal domain inhibitor (BETi). METHODS MANIFEST (ClinicalTrails.gov identifier: NCT02158858 ), a global, open-label, nonrandomized, multicohort, phase II study, includes a cohort of JAKi-naïve patients with myelofibrosis treated with pelabresib and ruxolitinib. The primary end point is a spleen volume reduction of ≥ 35% (SVR35) at 24 weeks. RESULTS Eighty-four patients received ≥ 1 dose of pelabresib and ruxolitinib. The median age was 68 (range, 37-85) years; 24% of patients were intermediate-1 risk, 61% were intermediate-2 risk, and 16% were high risk as per the Dynamic International Prognostic Scoring System; 66% (55 of 84) of patients had a hemoglobin level of < 10 g/dL at baseline. At 24 weeks, 68% (57 of 84) achieved SVR35, and 56% (46 of 82) achieved a total symptom score reduction of ≥ 50% (TSS50). Additional benefits at week 24 included 36% (29 of 84) of patients with improved hemoglobin levels (mean, 1.3 g/dL; median, 0.8 g/dL), 28% (16 of 57) with ≥ 1 grade improvement in fibrosis, and 29.5% (13 of 44) with > 25% reduction in JAK2V617F-mutant allele fraction, which was associated with SVR35 response ( P = .018, Fisher's exact test). At 48 weeks, 60% (47 of 79) of patients had SVR35 response. Grade 3 or 4 toxicities seen in ≥ 10% patients were thrombocytopenia (12%) and anemia (35%), leading to treatment discontinuation in three patients. 95% (80 of 84) of the study participants continued combination therapy beyond 24 weeks. CONCLUSION The rational combination of the BETi pelabresib and ruxolitinib in JAKi-naïve patients with myelofibrosis was well tolerated and showed durable improvements in spleen and symptom burden, with associated biomarker findings of potential disease-modifying activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
- Hematology Unit, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology "Seràgnoli", Bologna, Italy.
- Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.
- University of Insubria, Varese, Italy.
- Memorial Sloan-Kettering Cancer Center, New York, NY.
ORCID-Profile: John Mascarenhas, Andrea Patriarca, Francesco Passamonti, Adam J Mead, Moshe Talpaz, Tim C P Somervaille, Mohamed E Salama, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Srdan Verstovsek, Claire Harrison, Vikas Gupta
Förderung
- Medical Research Council
- NCI NIH HHS
- Cancer Research UK
Zitieren
APA
Mascarenhas, J., Kremyanskaya, M., Patriarca, A., Palandri, F., Devos, T., Passamonti, F., Rampal, R. K., Mead, A. J., Hobbs, G., Scandura, J. M., Talpaz, M., Granacher, N., Somervaille, T. C. P., Hoffman, R., Wondergem, M. J., Salama, M. E., Colak, G., Cui, J., Kiladjian, J. J., …, & Gupta, V. (2023). MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01972
Vancouver
Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, et al. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01972
BibTeX
@article{Mascarenhas2023,
author = {Mascarenhas, John and Kremyanskaya, Marina and Patriarca, Andrea and Palandri, Francesca and Devos, Timothy and Passamonti, Francesco and Rampal, Raajit K and Mead, Adam J and Hobbs, Gabriella and Scandura, Joseph M and Talpaz, Moshe and Granacher, Nikki and Somervaille, Tim C P and Hoffman, Ronald and Wondergem, Marielle J and Salama, Mohamed E and Colak, Gozde and Cui, Jike and Kiladjian, Jean-Jacques and Vannucchi, Alessandro M and Verstovsek, Srdan and Curto-García, Natalia and Harrison, Claire and Gupta, Vikas},
title = {MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.01972}
}
EUVIMED